Cefprozil monohydrate (Cefprozil) is a second-generation cephalosporin-type antibiotic.

Cefprozil is particularly active against the Gram-positive organisms Streptococcus pyogenes, pneumoniae and agalactiae and against methicillin-susceptible Staphylococcus aureus. Cefprozil is also moderately active against Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, many Enterobacteriaceae and certain anaerobic organisms, and is relatively stable to hydrolysis by a number of beta-lactamases. [1] Cefprozil is a newer oral Cephalosporin with a spectrum of activity against organisms that include gram-positive and gram-negative pathogens. Cefprozil is active (susceptibility, less than or equal to 8 mg /mL; moderate susceptibility, 16 mg/mL; resistance, greater than or equal to 32 mg/mL) against gram-positive species such as streptococci, methicillin-susceptible staphylococci, and Listeria monocytogenes. [2] Cefprozil is at least as active as cefuroxime, cefaclor, and cephalexin against all organisms tested, but is fourfold less active than doxycycline against E coli and 16-fold less active than clarithromycin versus S pneumoniae. Cefprozil is as active as amoxicillin/clavulanate against K pneumoniae and E coli. [3]

Cefprozil results in the mean peak concentration (Cmax) in infant dogs (21.2 mg/mL) and adult dogs (27.8 mg/mL). Cefprozil results in the areas under the concentration-time curve (AUC, in infant dogs: 121 mg.hr/mL, in adult dogs: 130 mg.hr/mL), half-lives (T 1/2, in infant dogs: 4.7 hours, in adult dogs: 4.7 hours) or urinary recovery rates (UR, in infant dogs: 36.3%, in adult dogs: 34.7%) between the 2 groups. [4]